Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation

被引:14
作者
Homma, Sadamu
Sagawa, Yukiko
Komita, Hideo
Koido, Shigeo
Nagasaki, Eijiro
Ryoma, Yoshiki
Okamoto, Masato
机构
[1] Jikei Univ, Sch Med, Inst DNA Med, Dept Oncol,Minato Ku, Tokyo 1058461, Japan
[2] Jikei Univ, Sch Med, Inst DNA Med, Clin Data Bank, Tokyo, Japan
[3] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan
[4] Chugai Pharmacol Co Ltd, Post Marketing Clin Trial Dept, Tokyo 1038324, Japan
[5] Musashino Univ, Fac Pharm, Res Inst Pharmaceut Sci, Tokyo 2028585, Japan
关键词
hepatocellular carcinoma; OK-432; intratumoral injection; interferon-gamma; toll-like receptor 4; dendritic cell;
D O I
10.1007/s00262-006-0277-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Intratumoral (i.t.) injection of OK-432, a streptococcal preparation, into implanted tumors of mouse hepatocellular carcinoma (MIH-2) showed antitumor effect including tumor eradication. Intraperitoneal administration of same dose OK-432 did not exhibit tumor suppressive effect. In vitro cytotoxic test suggested that direct cytotoxic effect of OK-432 was not associated with antitumor activity by i.t.-OK-432 treatment. It was also found that Toll-like receptor 4 signaling was not involved in i.t.-OK-432 treatment. Three mice out of five, which had shown tumor eradication by i.t.-OK-432 treatment did not reject re-challenge of MIH-2 cells. Splenocytes from i.t.-OK-432 treated mice did not produce IFN-gamma by stimulation with MIH-2 cells in vitro, but produced abundant IFN-gamma by stimulation with OK-432. Immunofluorescence microscopy demonstrated that CD4+T cells, but not CD8+T cells, infiltrated to i.t.-OK-432 treated tumor tissue produced IFN-gamma. Tumor-infiltrating CD4+T cells from i.t.-OK-432 treated tumor tissue produced IFN-gamma by in vitro stimulation with OK-432 higher than those from untreated tumor tissue. IFN-gamma directly induced apoptosis of MIH-2 cells in vitro. Collectively, i.t.-OK-432 treatment induced priming of CD4+T cells to antigenecity of OK-432, and repetitive i.t.-OK-432 treatment induced IFN-gamma production from OK-432-sensitized CD4+T cells in tumor site, leading to apoptosis of MIH-2 cells susceptible to IFN-gamma.
引用
收藏
页码:1265 / 1274
页数:10
相关论文
共 27 条
[1]   Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator - Involvement of Toll-like receptor 4 [J].
Ahmed, SU ;
Okamoto, M ;
Oshikawa, T ;
Tano, T ;
Sasai, A ;
Kan, S ;
Hiroshima, T ;
Ohue, H ;
Moriya, Y ;
Ryoma, Y ;
Saito, M ;
Sato, M .
JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) :432-441
[2]  
Fujimoto T, 1997, J IMMUNOL, V158, P5619
[3]   Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma [J].
Himoto, T ;
Watanabe, S ;
Nishioka, M ;
Maeba, T ;
Tanaka, S ;
Saito, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (02) :127-131
[4]   Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12 [J].
Homma, S ;
Komita, H ;
Sagawa, Y ;
Ohno, T ;
Toda, G .
IMMUNOLOGY, 2005, 115 (04) :451-461
[5]   Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice [J].
Homma, S ;
Toda, G ;
Gong, JL ;
Kufe, D ;
Ohno, T .
JOURNAL OF GASTROENTEROLOGY, 2001, 36 (11) :764-771
[6]  
Ikehara Mizuki, 2004, J Exp Ther Oncol, V4, P79
[7]   Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice [J].
Irie, M ;
Homma, S ;
Komita, H ;
Zeniya, M ;
Kufe, D ;
Ohno, T ;
Toda, G .
INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) :238-245
[8]  
KAI S, 1979, CLIN EXP IMMUNOL, V37, P98
[9]  
Kim SY, 1998, CANCER-AM CANCER SOC, V83, P2054, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2054::AID-CNCR2>3.0.CO
[10]  
2-1